Bristol-Myers Squibb

Bristol-Myers Squibb, a US-based Pharmaceutical Preparation Manufacturing company, reported its latest carbon emissions for 2024. Total emissions for 2024 were approximately 2.01 billion kg CO2e. This included Scope 1 emissions of around 206.73 million kg CO2e, Scope 2 emissions (market-based) of approximately 104.65 million kg CO2e, and Scope 3 emissions totalling about 1.70 billion kg CO2e. Key Scope 3 contributors included purchased goods and services at approximately 1.22 billion kg CO2e, and upstream transportation and distribution at about 149.09 million kg CO2e.

Looking back, in 2023, the company's total emissions were approximately 2.12 billion kg CO2e, with Scope 1 at about 208.53 million kg CO2e, Scope 2 (market-based) at around 158.45 million kg CO2e, and Scope 3 at roughly 1.75 billion kg CO2e. In 2022, total emissions were approximately 2.14 billion kg CO2e, comprising about 212.28 million kg CO2e for Scope 1, approximately 160.55 million kg CO2e for Scope 2 (market-based), and roughly 1.77 billion kg CO2e for Scope 3.

Bristol-Myers Squibb has committed to several ambitious climate targets. The company aims to achieve net-zero greenhouse gas emissions across its entire value chain by 2050, validated by the Science Based Targets initiative (SBTi). This includes near-term SBTi targets to reduce absolute Scope 1 and 2 GHG emissions by 54.6% by 2033 from a 2022 base year. Additionally, Bristol-Myers Squibb commits to reduce absolute Scope 3 GHG emissions from fuel and energy-related activities by 54.6% within the same timeframe. The company also targets having 75% of its suppliers, by emissions, covering purchased goods and services, capital goods, and upstream transportation and distribution, set science-based targets by 2028. For the long-term, Bristol-Myers Squibb commits to reduce absolute Scope 1 and 2 GHG emissions by 90% by 2050 from a 2022 base year, and absolute Scope 3 GHG emissions by 90% within the same timeframe.